All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ST02
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ST02
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Using a heart failure animal model, Saillant found out that the new treatment (ST02) restored heart function in failing hearts after four weeks of treatment. Treated hearts reversed to normal geometry with a significant reduction in scar tissue (fibrosis).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ORM-11372
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ORM-11372
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Orion Biotechnology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
AnaBios provided ex vivo data from human heart tissue to assess the pro-arrhythmic risk of the new NCX1.1 inhibitor, ORM-11372 (developed in Orion Pharma).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 17, 2020
Details:
The acquired PCSK9 inhibitors are small molecules that bind directly to a novel part of PCSK9 and have shown to block its activity and lower LDL cholesterol in preclinical models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CTP-Amio
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding July 15, 2020
Details:
This Phase I STTR award will accelerate the development of CTP-amio and will set the stage for larger animal model studies and full pharmacology/toxicity studies of CTP-amio in preparation for filing an Investigational New Drug application for a Phase I clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NYX-PCSK9i
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
According to pre-clinical results, the cells showed an increase in LDL receptor levels and demonstrated equivalency to marketed monoclonal PCSK9 antibody drugs, evolocumab and alirocumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene-editing therapies
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $63.0 million Upfront Cash: Undisclosed
Deal Type: Series A2 Financing June 11, 2020
Details:
The company will use the financing to advance its lead program through IND-enabling studies and fuel follow-on pipeline programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PP-002
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-002
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Qingdao Primedicine Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 19, 2020
Details:
Under the terms of the Partnership, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
Details:
Three posters illustrate advances made with Tenaya's Cellular Regeneration platform using direct reprogramming of resident cardiac fibroblasts to create new cardiomyocytes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PP-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-001
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Simcere Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 11, 2020
Details:
Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neurokinin 1 receptor positive mesenchymal stem cell
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
Animal research findings show substantial improvements in heart function for heart failure subjects treated with BioCardia's allogeneic neurokinin 1 receptor positive mesenchymal stem cell, CardiALLOTM.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
